Asymptomatic hyperuricaemia

Asymptomatic hyperuricaemia is defined as an elevated serum urate level (>0.42 mmol/L in men and post-menopausal women; >0.36 mmol/L in pre-menopausal women) in the absence of gout, gouty arthritis, or uric acid nephrolithiasis. It is an extremely common biochemical finding in the Australian general population, particularly in males. The clinical significance and whether to treat asymptomatic hyperuricaemia remains an area of active debate and evolving evidence.

Uric acid is the final oxidation product of purine metabolism in humans, produced primarily in the liver and excreted by the kidneys (two-thirds) and gastrointestinal tract (one-third). Hyperuricaemia results from overproduction of uric acid, underexcretion, or a combination of both.

Causes of Asymptomatic Hyperuricaemia

Why Not All Hyperuricaemia Progresses to Gout

• MSU crystal deposition requires sustained supersaturation — episodic elevations may not trigger crystallisation
• Local tissue factors influence crystallisation: temperature (peripheral joints cooler), pH, proteoglycans
• Immunological variation — some individuals mount less inflammatory response to crystals
• Duration of hyperuricaemia matters — risk increases with duration and magnitude of serum urate elevation

By definition, asymptomatic hyperuricaemia produces no clinical signs or symptoms attributable to urate deposition. It is typically discovered incidentally on routine blood tests or metabolic screening.

Associated Conditions

Hyperuricaemia is strongly associated with several metabolic and cardiovascular conditions, although causal relationships are debated:

• Metabolic syndrome: Central obesity, hypertriglyceridaemia, hypertension, insulin resistance — up to 70% of patients with gout have metabolic syndrome
• Hypertension: Independent association — hyperuricaemia may cause endothelial dysfunction and renal afferent arteriolar vasoconstriction
• Chronic kidney disease: Bidirectional relationship — CKD causes hyperuricaemia (reduced excretion), and hyperuricaemia may accelerate CKD progression
• Cardiovascular disease: Independent risk factor for cardiovascular events in observational studies; RCT evidence for benefit of ULT on CV outcomes is mixed
• Non-alcoholic fatty liver disease (NAFLD): Associated with hyperuricaemia via fructose metabolism and metabolic syndrome
• Type 2 diabetes: Insulin resistance impairs renal urate excretion

The investigation of incidentally discovered hyperuricaemia aims to identify reversible secondary causes, assess renal function, and evaluate cardiovascular metabolic risk. Extensive investigation is not required for all patients — tailor to clinical context.

• Essential
  Serum urate (repeat confirmatory)

  Confirm on fasting sample — avoid testing during acute illness, following alcohol, or during fasting. Confirm genuinely elevated on repeat.
• Essential
  Renal function (UEC, eGFR)

  CKD is a major cause and consequence of hyperuricaemia. Baseline renal function essential. Urate >0.48 mmol/L with CKD carries higher risk of progression.
• Essential
  Urine dipstick / urinalysis

  Assess for proteinuria (CKD), haematuria (nephrolithiasis). If nephrolithiasis suspected, urine pH — uric acid stones form in acidic urine, pH <5.5.
• Recommended
  Fasting lipids, glucose, HbA1c

  Metabolic syndrome screening. Dyslipidaemia and glucose intolerance commonly co-exist. Cardiovascular risk assessment.
• Recommended
  Blood pressure and BMI

  Hypertension and obesity are both causes and associated comorbidities. Document at time of hyperuricaemia identification.
• Recommended
  FBC

  Exclude haematological causes of overproduction: polycythaemia, myeloid disorders, haemolytic anaemia.
• Recommended
  LFT and TSH

  Exclude hypothyroidism (underexcretion) and hepatic disease. Baseline LFTs if ULT is being considered in the future.
• Available
  24-hour urine uric acid

  Distinguishes overproduction (>800 mg/day on regular diet) from underexcretion. Useful if metabolic work-up or enzyme defect suspected in young patients.
• Available
  Imaging (X-ray, renal ultrasound)

  Not routinely required. Renal ultrasound if nephrolithiasis suspected. Joint X-ray not indicated in asymptomatic hyperuricaemia without joint symptoms.

Risk stratification in asymptomatic hyperuricaemia guides monitoring intensity and the threshold for considering pharmacological treatment in the future. The main stratification factors are the degree of hyperuricaemia, renal function, and associated comorbidities.

Factors Favouring Earlier Treatment Consideration

• Serum urate persistently >0.54 mmol/L (very high burden — higher crystallisation risk)
• CKD stage 3 or worse — emerging evidence that ULT may slow CKD progression
• Solid organ transplant recipient on ciclosporin
• Recurrent uric acid nephrolithiasis
• Patient expressing preference for pharmacological treatment after full discussion of risks and limited evidence
• Strong family history of gout with rising urate trajectory

Pharmacological urate-lowering therapy (ULT) is NOT indicated for asymptomatic hyperuricaemia as routine practice. Medications used when treatment is indicated (nephrolithiasis, very high-risk CKD, transplant) are the same as for gout management.

When Pharmacological Treatment May Be Appropriate

• Recurrent uric acid nephrolithiasis: Allopurinol with urine alkalinisation (potassium citrate) — ULT is indicated
• Transplant recipient on ciclosporin with serum urate >0.54 mmol/L: Discuss ULT with transplant team (note allopurinol + azathioprine contraindication)
• CKD stage 3+ with persistent serum urate >0.54 mmol/L: Consider ULT after discussing current evidence limitations and risks
• Oncology — tumour lysis syndrome prevention: Allopurinol (or rasburicase for high-risk) before cytotoxic therapy

Urine Alkalinisation for Uric Acid Nephrolithiasis

The cornerstone of asymptomatic hyperuricaemia management is addressing modifiable risk factors. Lifestyle modification can reduce serum urate by 0.06–0.12 mmol/L — meaningful in borderline cases and important for cardiovascular health regardless of urate effect.

Dietary Modifications

• Reduce purine intake: Limit organ meats (liver, kidney), red meat, seafood (anchovies, sardines, mussels, shellfish)
• Reduce alcohol: Beer and spirits are strongly uricogenic; wine has less effect; ideally abstain or limit to <2 standard drinks/day
• Avoid fructose: Sugar-sweetened beverages, fruit juices, high-fructose corn syrup — fructose promotes uric acid synthesis
• Increase low-fat dairy: Associated with lower serum urate (uricosuric proteins in dairy)
• Increase hydration: Minimum 2 L fluid/day — promotes renal urate excretion
• Weight loss: Significant reduction in serum urate with 5–10% weight loss
• Coffee: Regular coffee consumption associated with lower serum urate (xanthine oxidase inhibition by chlorogenic acid)

Medication Review

• Review and substitute urate-elevating medications where clinically safe
• Thiazide diuretics: Switch to amlodipine or losartan if hypertension is the indication — losartan has a mild uricosuric effect
• Loop diuretics: Substitute if clinically appropriate; if for heart failure, continue and manage urate separately
• Low-dose aspirin: Continue if cardioprotective — benefit outweighs urate elevation
• Ciclosporin: Switch to tacrolimus if feasible (less uricogenic) — in consultation with transplant team

Comorbidity Management

• Treat hypertension — preferring losartan as antihypertensive where suitable
• Manage obesity and metabolic syndrome — weight loss is the most effective lifestyle intervention for hyperuricaemia
• Manage dyslipidaemia and glucose independently of hyperuricaemia — cardiovascular risk reduction is important regardless of urate effect
• Manage CKD with nephrology if eGFR <45 mL/min — hyperuricaemia in CKD is common and monitoring frequency increases

Non-pharmacological management forms the entire treatment strategy for most patients with asymptomatic hyperuricaemia. The focus is patient education, lifestyle optimisation, and appropriate monitoring rather than medication.

Patient Education — Key Messages

• An elevated uric acid level alone does not cause symptoms — it does not need to be treated with medication unless gout or kidney stones develop
• The elevated uric acid is often a marker of dietary and lifestyle factors that can be improved
• Most people with elevated uric acid will never get gout — but the risk increases the higher and longer the level is elevated
• Monitoring the level annually and addressing diet, weight, alcohol, and medications is appropriate management
• Report any joint pain, especially sudden severe pain in the big toe, ankle, or knee — this may be a first gout attack and should prompt re-evaluation
• Report any passing of kidney stones or blood in urine

Monitoring Plan for Asymptomatic Hyperuricaemia

Monitoring asymptomatic hyperuricaemia involves periodic serum urate measurement, renal function assessment, and cardiovascular risk surveillance. The intensity of monitoring scales with urate level and comorbidity burden.

When to Refer

• Rheumatology: Serum urate persistently >0.54 mmol/L with CKD or cardiovascular disease — to discuss evidence and individualised ULT decision
• Nephrology: CKD stage 3+ with hyperuricaemia — co-management of renal disease and urate
• Urology/Nephrology: Recurrent uric acid nephrolithiasis — ULT and alkalinisation required
• Endocrinology: If secondary cause suspected (hyperparathyroidism, hypothyroidism not responding to simple measures)

Several populations require modified approaches to asymptomatic hyperuricaemia.

Young Adults (<40 Years) with Hyperuricaemia

• Warrants more thorough investigation — consider rare metabolic causes (HGPRT deficiency, PRPP overactivity, familial juvenile hyperuricaemic nephropathy)
• Check for lead nephropathy in occupational exposure history
• Renal imaging and urine uric acid:creatinine ratio
• Genetic counselling if enzyme defect suspected
• More aggressive lifestyle intervention given decades of exposure ahead

Hyperuricaemia in Pregnancy

• Uric acid normally rises in pregnancy, particularly in the third trimester
• Elevated urate in pregnancy is associated with pre-eclampsia — but serum urate is not used to diagnose or manage pre-eclampsia (other criteria apply)
• Allopurinol is category C — avoid unless compelling indication
• NSAIDs contraindicated after 20 weeks
• Manage as obstetric issue if pre-eclampsia suspected; refer to obstetrics

Hyperuricaemia with Cardiovascular Disease

• Hyperuricaemia is an independent predictor of cardiovascular events in epidemiological studies
• However, RCT evidence does not clearly show cardiovascular benefit from ULT in asymptomatic hyperuricaemia
• Manage cardiovascular risk factors (BP, lipids, glucose, smoking, weight) aggressively
• Consider ULT if serum urate very high (>0.54 mmol/L) — discuss evolving evidence with patient; rheumatology input

Transplant Recipients

• Ciclosporin causes severe hyperuricaemia — up to 80% develop gout post-transplant
• Asymptomatic hyperuricaemia in transplant recipients warrants closer monitoring (3–6 monthly urate)
• Switch to tacrolimus if feasible (less uricogenic)
• Allopurinol contraindicated with azathioprine — see gout guideline for management
• Early intervention before gout develops is reasonable in transplant recipients on ciclosporin

The key stewardship concern in asymptomatic hyperuricaemia is inappropriate prescribing of urate-lowering therapy without clinical indication. This exposes patients to medication side effects (including rare but fatal allopurinol hypersensitivity) without proven benefit.

GP Role

• Identify and address reversible causes before considering pharmacological treatment
• Do not prescribe allopurinol for asymptomatic hyperuricaemia without clear indication (nephrolithiasis, transplant, very high-risk CKD)
• Educate patients about the difference between asymptomatic hyperuricaemia and gout — many patients are anxious about a high uric acid level
• Integrate monitoring into annual health checks — do not require separate visits for urate surveillance
• Know when to refer — rheumatology for complex cases, nephrology for CKD co-management

The primary aim of follow-up in asymptomatic hyperuricaemia is prevention of gout, nephrolithiasis, and monitoring for comorbidity progression. Most patients require only annual surveillance with lifestyle reinforcement.

Prevention

• Prevention of gout in asymptomatic hyperuricaemia: sustained lifestyle modification (weight, diet, alcohol, hydration)
• Prevention of nephrolithiasis: high fluid intake, urine alkalinisation if pH persistently <5.5
• Prevention of CKD progression: control BP, weight, glucose — hyperuricaemia management secondary to these in asymptomatic patients
• Patient empowerment: clear instruction to present if joint symptoms develop — early gout treatment prevents progression

• 01
  FitzGerald JD, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol. 2020;72(6):879–895.
• 02
  Richette P, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
• 03
  Therapeutic Guidelines. Rheumatology. Melbourne: Therapeutic Guidelines Ltd; 2024.
• 04
  Dalbeth N, et al. Gout. Lancet. 2016;388(10055):2039–2052.
• 05
  Badve SV, et al. Effects of allopurinol on the progression of chronic kidney disease (CKD-FIX trial). NEJM. 2020;382(26):2504–2513.
• 06
  Dougan M, et al. PERL trial: Effects of intensive urate lowering on progression of diabetic kidney disease. Diabetes Care. 2022;45(2):349–358.
• 07
  Stamp LK, Merriman TR, Barclay ML. Pharmacology and pharmacogenomics of urate-lowering therapy. Rheum Dis Clin North Am. 2014;40(2):327–352.
• 08
  Borghi C, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729–1741.
• 09
  Australian Bureau of Statistics. Health Conditions Prevalence, 2017–18. Canberra: ABS; 2018.
• 10
  Royal Australian College of General Practitioners (RACGP). Guidelines for preventive activities in general practice (Red Book). 10th ed. Melbourne: RACGP; 2023.
• 11
  Pharmaceutical Benefits Scheme (PBS). Schedule of Pharmaceutical Benefits. Canberra: Department of Health; 2025.